These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7259326)

  • 21. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis.
    Zachariae H; Halkier-Sørensen L; Bjerring P; Heickendorff L
    Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of prostaglandin E1 (lipo-PGE1) to treat Raynaud's phenomenon associated with connective tissue disease: thermographic and subjective assessment.
    Katoh K; Kawai T; Narita M; Uemura J; Tani K; Okubo T
    J Pharm Pharmacol; 1992 May; 44(5):442-4. PubMed ID: 1359062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.
    McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ
    Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome.
    Lucas GS; Simms MH; Caldwell NM; Alexander SJ; Stuart J
    J Clin Pathol; 1984 Aug; 37(8):870-3. PubMed ID: 6540787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low molecular weight dextran in systemic sclerosis and Raynaud's phenomenon.
    Dodman B; Rowell NR
    Acta Derm Venereol; 1982; 62(5):440-2. PubMed ID: 6183899
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment of Raynaud's Syndrome with prostacyclin.
    Belch JJ; Newman P; Drury JK; Capell H; Leiberman P; James WB; Forbes CD; Prentice CR
    Thromb Haemost; 1981 Jun; 45(3):255-6. PubMed ID: 7025341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
    Mittag M; Beckheinrich P; Haustein UF
    Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal application of prostaglandin E1 ethyl ester for the treatment of trophic acral skin lesions in a patient with systemic scleroderma.
    Schlez A; Kittel M; Scheurle B; Diehm C; Jünger M
    J Eur Acad Dermatol Venereol; 2002 Sep; 16(5):526-8. PubMed ID: 12428854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
    Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
    Mizushima Y; Shiokawa Y; Homma M; Kashiwazaki S; Ichikawa Y; Hashimoto H; Sakuma A
    J Rheumatol; 1987 Feb; 14(1):97-101. PubMed ID: 3553591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Thermographic assessment of Raynaud's phenomenon in childhood mixed connective tissue disease].
    Yokota S; Kuriyama T; Takahashi Y; Mori M; Shike H; Ibe M; Mitsuda T; Aihara Y
    Ryumachi; 1994 Dec; 34(6):955-60. PubMed ID: 7863385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.